# What Is a Contingent Value Right?

Published: 2026-02-09
Author: Warren Team
URL: https://www.heywarren.com/blog/contingent-value-right

---
When Sanofi acquired Genzyme in 2011 for $20.1 billion, shareholders didn't walk away with just cash — they also received a contingent value right worth up to $3.8 billion more, tied entirely to the commercial performance of a single experimental drug. Most investors had never heard of such an instrument before. Many still haven't.

That knowledge gap is costly. A contingent value right can add meaningful dollars to a deal — or evaporate completely — depending on outcomes that unfold years after a merger closes. Yet most retail investors treat CVRs as an afterthought, misread their terms, or sell them for pennies before the payout window even opens.

In this guide, you'll learn exactly what a contingent value right is, how it functions inside a merger or acquisition, and how to evaluate whether a CVR is worth holding or selling. You'll also see how real shareholders have gained — and lost — by misunderstanding this deceptively simple instrument.

According to Dealogic data, pharmaceutical and biotech deals account for more than 60% of all CVR issuances, making this one of the most sector-specific financial instruments in mergers and [acquisitions](/blog/what-is-acquisitions).

---

## What Is a Contingent Value Right?

A contingent value right (CVR) is a contract entitling shareholders to receive additional cash or shares if a specific milestone is achieved within a defined period, typically after a merger or acquisition closes. Think of it as a conditional bonus: the acquiring company promises more money later, but only if something measurable happens first.

![The four main categories of events that can trigger a contingent value right payout.](data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20viewBox%3D%220%200%20760%20211%22%20width%3D%22760%22%20height%3D%22211%22%20role%3D%22img%22%3E%3Ctitle%3EHierarchy%3C%2Ftitle%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23f8fafc%22%2F%3E%3Crect%20x%3D%22300%22%20y%3D%2220%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22%232563eb%22%2F%3E%3Ctext%20x%3D%22380%22%20y%3D%2254%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2214%22%20font-weight%3D%22700%22%20fill%3D%22white%22%3ECVR%20Milestone%3C%2Ftext%3E%3Cpath%20d%3D%22M%20380%2078%20L%20380%20105.5%20L%20110%20105.5%20L%20110%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%2230%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22110%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EFDA%20Approval%3C%2Ftext%3E%3Ctext%20x%3D%22110%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EDrug%20cleared%20for%20market%3C%2Ftext%3E%3Cpath%20d%3D%22M%20380%2078%20L%20380%20105.5%20L%20290%20105.5%20L%20290%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%22210%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22290%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3ERevenue%20Target%3C%2Ftext%3E%3Ctext%20x%3D%22290%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3Ee.g.%20%24500M%20net%20sales%3C%2Ftext%3E%3Cpath%20d%3D%22M%20380%2078%20L%20380%20105.5%20L%20470%20105.5%20L%20470%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%22390%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22470%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EClinical%20Data%3C%2Ftext%3E%3Ctext%20x%3D%22470%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EPhase%20III%20outcome%3C%2Ftext%3E%3Cpath%20d%3D%22M%20380%2078%20L%20380%20105.5%20L%20650%20105.5%20L%20650%20133%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%20fill%3D%22none%22%2F%3E%3Crect%20x%3D%22570%22%20y%3D%22133%22%20width%3D%22160%22%20height%3D%2258%22%20rx%3D%228%22%20fill%3D%22white%22%20stroke%3D%22%230891b2%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22650%22%20y%3D%22158%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2213%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3ELitigation%3C%2Ftext%3E%3Ctext%20x%3D%22650%22%20y%3D%22176%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ESettlement%20or%20verdict%3C%2Ftext%3E%3C%2Fsvg%3E)

*The four main categories of events that can trigger a contingent value right payout.*

CVRs are most common in pharmaceutical mergers, where the value of a pipeline drug is uncertain at deal close. Instead of pricing that uncertainty into the upfront offer — which could kill a deal — the acquirer separates it. You get certainty now in the form of the base cash price, and optionality later through the CVR payout.

The milestone triggering payment can be almost anything the two parties negotiate:

- **FDA approval** of a drug currently in clinical trials
- **Revenue targets** — for example, $500 million in annual [net sales](/blog/calculate-net-sales) by Year 3
- **Clinical trial outcomes** — positive Phase III data by a specific calendar date
- **Litigation settlements** — resolution of a major lawsuit in favor of the acquired company

CVRs are typically non-transferable, meaning they cannot be sold on a secondary market, though exceptions exist. They expire if the milestone is not met by the contract deadline, leaving holders with nothing.

---

## How Contingent Value Rights Work

A CVR functions as a written agreement between the acquiring company and the shareholders of the acquired company. The terms are filed with the SEC, and a **rights agent** — usually a bank or trust company — administers the process independently of both parties.

![From deal close to payout or expiration, a CVR passes through four distinct stages before shareholders know their outcome.](data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20viewBox%3D%220%200%20800%20149%22%20width%3D%22800%22%20height%3D%22149%22%20role%3D%22img%22%3E%3Ctitle%3ETimeline%3C%2Ftitle%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23f8fafc%22%2F%3E%3Cline%20x1%3D%22137.5%22%20y1%3D%2255%22%20x2%3D%22662.5%22%20y2%3D%2255%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%223%22%2F%3E%3Ccircle%20cx%3D%22137.5%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22137.5%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E1%3C%2Ftext%3E%3Ctext%20x%3D%22137.5%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EDeal%20Closes%3C%2Ftext%3E%3Ctext%20x%3D%22137.5%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ECVR%20issued%20per%20share%3C%2Ftext%3E%3Ccircle%20cx%3D%22312.5%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22312.5%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E2%3C%2Ftext%3E%3Ctext%20x%3D%22312.5%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EMilestone%20Window%3C%2Ftext%3E%3Ctext%20x%3D%22312.5%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3EAcquirer%20pursues%20target%3C%2Ftext%3E%3Ccircle%20cx%3D%22487.5%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22%232563eb%22%20stroke%3D%22%232563eb%22%20stroke-width%3D%223%22%2F%3E%3Ctext%20x%3D%22487.5%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22white%22%3E3%3C%2Ftext%3E%3Ctext%20x%3D%22487.5%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EMilestone%20Met%3F%3C%2Ftext%3E%3Ctext%20x%3D%22487.5%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ERights%20agent%20verifies%3C%2Ftext%3E%3Ccircle%20cx%3D%22662.5%22%20cy%3D%2255%22%20r%3D%2224%22%20fill%3D%22white%22%20stroke%3D%22%23cbd5e1%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22662.5%22%20y%3D%2260%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2215%22%20font-weight%3D%22700%22%20fill%3D%22%230f172a%22%3E4%3C%2Ftext%3E%3Ctext%20x%3D%22662.5%22%20y%3D%22101%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2212%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EPayout%20or%20Zero%3C%2Ftext%3E%3Ctext%20x%3D%22662.5%22%20y%3D%22119%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2210%22%20fill%3D%22%2364748b%22%3ECash%20in%2015%E2%80%9330%20days%3C%2Ftext%3E%3C%2Fsvg%3E)

*From deal close to payout or expiration, a CVR passes through four distinct stages before shareholders know their outcome.*

### The Structure of a CVR Agreement

Every CVR agreement contains four core components:

1. **The milestone definition** — precisely what must happen (e.g., "FDA approval of Drug X by December 31, 2027")
2. **The payout amount** — the dollar figure per CVR if the milestone is achieved
3. **The expiration date** — the hard deadline by which the milestone must be met
4. **The rights agent** — the neutral third party that certifies milestone achievement and distributes payments

The acquiring company has a contractual duty to use "commercially reasonable efforts" to hit the milestone. That phrase is heavily negotiated and frequently litigated, because acquirers sometimes have weaker incentives to pursue a milestone after the deal closes.

### How Payment Gets Distributed

When the milestone is met, the rights agent verifies the triggering event and notifies shareholders. Payment typically follows within 15 to 30 business days under most agreement terms.

If you held 1,000 shares of the target company and each share came with one CVR worth $2.00 upon FDA approval, you would receive $2,000 — on top of whatever upfront merger consideration you already received.

If the milestone is not met before the expiration date, the CVR expires worthless. There is no partial payment, no extension, and no appeal process for ordinary holders.

---

## Why Companies Issue Contingent Milestone Payments

CVRs exist because mergers often collapse over valuation disagreements. A target company's board believes the pipeline is worth $5 billion; the acquirer's model says $3 billion. Neither side wants to walk away, but neither will move enough to close the gap.

A CVR bridges that gap by converting a pricing argument into a shared bet. The target shareholders accept the lower upfront price but retain upside if they are right. The acquirer limits its downside by paying more only if the asset actually performs.

### CVRs as Deal-Closing Mechanisms

In competitive bidding situations, CVRs let acquirers enhance total deal value without increasing the certain cash outflow. Bristol-Myers Squibb used exactly this tactic in its $74 billion acquisition of Celgene in 2019, attaching a CVR worth up to $9 per share tied to FDA approval of three specific drugs. The contingent payment made the deal economically competitive without requiring BMS to pay $9 more per share upfront.

This structure is especially valuable in biotech, where drug success rates vary dramatically. Roughly 12% of drugs entering Phase I clinical trials ultimately reach FDA approval, according to MIT research. Pricing that uncertainty into an upfront offer heavily favors the acquirer; CVRs split the risk more fairly.

### CVRs as Shareholder Protection Tools

From the shareholder's perspective, a CVR prevents the acquirer from buying a company cheaply and then capturing all the upside from a successful drug or litigation resolution. If the asset turns out to be worth more than the deal price implied, original shareholders participate in that additional value rather than losing it to the buyer.

This protective function matters most when a board accepts a deal under pressure — a hostile takeover bid, a looming patent cliff, or intense regulatory scrutiny. A well-structured CVR can secure shareholder votes that might otherwise block a [transaction](/blog/what-is-a-transactions).

---

## Real-World Examples of CVR Outcomes

Looking at actual CVR results teaches more than theory ever could. Some have paid out handsomely. Many have expired worthless.

![All three drug approvals were required; one missed its deadline, zeroing out the entire $9-per-share CVR payout.](data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20viewBox%3D%220%200%20875%20125%22%20width%3D%22875%22%20height%3D%22125%22%20role%3D%22img%22%3E%3Ctitle%3EFlow%20diagram%3C%2Ftitle%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22%23f8fafc%22%2F%3E%3Crect%20x%3D%2230%22%20y%3D%2225%22%20width%3D%22170%22%20height%3D%2275%22%20rx%3D%2210%22%20fill%3D%22white%22%20stroke%3D%22%232563eb%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22115%22%20y%3D%2258.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2214%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EOzanimod%3C%2Ftext%3E%3Ctext%20x%3D%22115%22%20y%3D%2278.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2211%22%20fill%3D%22%2364748b%22%3EApproved%20in%20time%3C%2Ftext%3E%3Cline%20x1%3D%22205%22%20y1%3D%2262.5%22%20x2%3D%22237%22%20y2%3D%2262.5%22%20stroke%3D%22%2364748b%22%20stroke-width%3D%222%22%2F%3E%3Cpolygon%20points%3D%22244%2C62.5%20235%2C57.5%20235%2C67.5%22%20fill%3D%22%2364748b%22%2F%3E%3Crect%20x%3D%22245%22%20y%3D%2225%22%20width%3D%22170%22%20height%3D%2275%22%20rx%3D%2210%22%20fill%3D%22white%22%20stroke%3D%22%232563eb%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22330%22%20y%3D%2258.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2214%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3ELiso-cel%3C%2Ftext%3E%3Ctext%20x%3D%22330%22%20y%3D%2278.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2211%22%20fill%3D%22%2364748b%22%3EApproved%20in%20time%3C%2Ftext%3E%3Cline%20x1%3D%22420%22%20y1%3D%2262.5%22%20x2%3D%22452%22%20y2%3D%2262.5%22%20stroke%3D%22%2364748b%22%20stroke-width%3D%222%22%2F%3E%3Cpolygon%20points%3D%22459%2C62.5%20450%2C57.5%20450%2C67.5%22%20fill%3D%22%2364748b%22%2F%3E%3Crect%20x%3D%22460%22%20y%3D%2225%22%20width%3D%22170%22%20height%3D%2275%22%20rx%3D%2210%22%20fill%3D%22white%22%20stroke%3D%22%232563eb%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22545%22%20y%3D%2258.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2214%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3EIde-cel%3C%2Ftext%3E%3Ctext%20x%3D%22545%22%20y%3D%2278.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2211%22%20fill%3D%22%2364748b%22%3EMissed%20deadline%3C%2Ftext%3E%3Cline%20x1%3D%22635%22%20y1%3D%2262.5%22%20x2%3D%22667%22%20y2%3D%2262.5%22%20stroke%3D%22%2364748b%22%20stroke-width%3D%222%22%2F%3E%3Cpolygon%20points%3D%22674%2C62.5%20665%2C57.5%20665%2C67.5%22%20fill%3D%22%2364748b%22%2F%3E%3Crect%20x%3D%22675%22%20y%3D%2225%22%20width%3D%22170%22%20height%3D%2275%22%20rx%3D%2210%22%20fill%3D%22white%22%20stroke%3D%22%232563eb%22%20stroke-width%3D%222%22%2F%3E%3Ctext%20x%3D%22760%22%20y%3D%2258.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2214%22%20font-weight%3D%22600%22%20fill%3D%22%230f172a%22%3E%240%20Payout%3C%2Ftext%3E%3Ctext%20x%3D%22760%22%20y%3D%2278.5%22%20text-anchor%3D%22middle%22%20font-family%3D%22system-ui%2C-apple-system%2Csans-serif%22%20font-size%3D%2211%22%20fill%3D%22%2364748b%22%3EAll%203%20required%3C%2Ftext%3E%3C%2Fsvg%3E)

*All three drug approvals were required; one missed its deadline, zeroing out the entire $9-per-share CVR payout.*

### The Sanofi-Genzyme CVR (2011)

Sanofi's acquisition of Genzyme included a tradeable CVR — listed on NASDAQ under the ticker "GCVRZ" — paying up to $14 per CVR share tied to sales milestones for Lemtrada (alemtuzumab), a multiple sclerosis drug. Initial trading prices sat around $1.00, reflecting deep market skepticism about peak sales potential.

Lemtrada received FDA approval in 2014. Partial milestone payments were made to CVR holders. But achieving the full sales thresholds proved far more difficult than proponents projected, and many investors who held through the entire window received substantially less than the headline $14. The Sanofi-Genzyme CVR became a masterclass in reading milestone definitions carefully rather than trusting the maximum payout figure.

### The Bristol-Myers Squibb–Celgene CVR (2019)

BMS issued one CVR per Celgene share, promising $9.00 if three drugs — ozanimod, liso-cel, and ide-cel — all received FDA approval by specified dates. Two of the three drugs cleared FDA approval within the window. Ide-cel, the third drug, received approval but missed its original CVR deadline by roughly two months, having been delayed and resubmitted under a revised timeline.

Because all three conditions were required, missing one threshold zeroed out the entire payment. The CVR expired worthless despite two successful approvals. This outcome illustrates the binary nature of multi-condition CVR structures: a single miss can eliminate a payout even when most milestones are achieved.

### Litigation CVRs in Corporate Divestitures

Not every CVR is tied to drug development. In some divestitures, CVRs are tied to the resolution of pending litigation. If a company sells a subsidiary while a major patent lawsuit is unresolved, sellers may receive a CVR entitling them to a share of any future settlement proceeds. These **litigation CVRs** are harder to value using conventional financial models, but they can generate significant payouts years after the underlying deal closes.

---

## Risks Every Investor Should Understand

CVRs are not free money added to a deal. They carry distinct risks that investors — including sophisticated institutional players — regularly underestimate.

### Milestone Failure Risk

This is the primary risk. Biotech drug development has a notoriously high attrition rate. A drug can fail in Phase III trials even after promising Phase II data, erasing CVR value overnight. Revenue milestones can be missed due to competitive pricing pressure, slow physician adoption, or unexpected adverse events that limit the patient population.

Always read the exact milestone definition in the SEC filing. Vague language like "substantial completion" invites disputes. Precise thresholds like "$500 million in net sales" are more verifiable — but also easier to miss by a narrow margin.

### Incentive Misalignment After Closing

After a deal closes, the acquiring company controls resource allocation for milestone pursuit. "Commercially reasonable efforts" is the legal standard in most CVR agreements, but it does not mean "best efforts." An acquirer can deprioritize a drug in favor of its own existing pipeline and still technically satisfy its contractual obligation.

This misalignment of incentives is a structural flaw baked into most CVR designs. Shareholders cannot easily monitor day-to-day research and commercialization decisions, and litigation to enforce the "commercially reasonable efforts" standard is expensive, slow, and unpredictable.

### Illiquidity and Binary Expiration

Most CVRs are non-transferable. You cannot sell them, borrow against them, or hedge them. If you need liquidity before the milestone window closes, you have no exit. Tradeable CVRs like the Sanofi-Genzyme instrument are rare exceptions, not the standard structure.

If the expiration date passes without milestone achievement, the CVR expires at exactly zero — no partial recovery, no secondary market, no consolation payment.

---

## How to Evaluate a CVR Before Accepting a Deal

If you're a shareholder in a company being acquired and the deal includes a contingent payment instrument, ask these questions before deciding whether to support the transaction.

**1. How specific is the milestone?**
Precisely defined, objectively verifiable milestones are far preferable to subjective ones. If the trigger requires interpretation, assume it will be interpreted against shareholders in any dispute.

**2. What is the independent probability of milestone achievement?**
For drug CVRs, review Phase trial data, comparable drug approval rates, and independent analyst research. For revenue CVRs, examine addressable market size, competitive dynamics, and historical sales trends in the therapeutic area. Do not rely solely on the acquirer's projections.

**3. What are the acquirer's incentives post-close?**
If the acquiring company already has a competing product in the same therapeutic area, their motivation to aggressively commercialize your CVR-linked asset is structurally lower. Conflict of interest analysis is essential, not optional.

**4. How long is the milestone window?**
A three-year window is tight for early-stage drug development. A seven-year window for a late-stage asset nearing approval may be more than sufficient. Match the timeline to the realistic development or commercialization trajectory of the underlying asset.

**5. Does the base deal price stand on its own?**
If the upfront cash offer fairly values the company without any CVR contribution, the CVR represents pure optionality layered on top. If the board accepted a below-market base price in exchange for attaching a CVR, you are being asked to bet on an uncertain outcome just to receive fair compensation.

---

## Related Reading

**More from Warren**:
- [What Does It Mean When a Will Is Probated?](/blog/will-is-probated)
- [What Is the Rates of Change Formula?](/blog/rates-of-change-formula)

## Authoritative Sources

For deeper background and primary-source data on this topic, the following authoritative sources are useful starting points:

- [IRS](https://www.irs.gov/)
- [SEC](https://www.sec.gov/)
- [Federal Reserve](https://www.federalreserve.gov/)
- [Consumer Financial Protection Bureau](https://www.consumerfinance.gov/)
- [U.S. Department of the Treasury](https://home.treasury.gov/)
- [Bureau of Labor Statistics](https://www.bls.gov/)

## Conclusion

[Contingent value rights](/blog/contingent-value-rights) are among the most misunderstood instruments in mergers and acquisitions — and among the most consequential for investors who do not take the time to understand them. Here are the key takeaways:

- A **contingent value right** is a post-closing payment promise tied to a specific, measurable milestone, most commonly FDA drug approval or defined revenue targets.
- CVRs bridge valuation gaps in deals where future asset value is genuinely uncertain, protecting sellers while limiting acquirer downside.
- The two biggest risks are milestone failure and acquirer incentive misalignment — both structural features of CVR design, not edge cases.
- Always read the full CVR agreement filed with the SEC, not just the merger press release summary. The precise milestone language, expiration date, and dispute resolution procedures only appear in the full document.
- For tradeable CVRs, compare your independent probability estimate against the implied market probability before deciding to hold or sell.

Whether you encounter a contingent value right as a target shareholder evaluating a buyout offer or as a secondary market buyer purchasing CVRs from other investors, the same principle applies: the instrument is worth exactly as much as the milestone probability and the acquirer's commitment to pursuing it. Do your own analysis before treating any CVR payout as guaranteed.

Ready to put this knowledge to work? Try Warren, your AI financial advisor — get personalized, conflict-free guidance at heywarren.com